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INSTRUCTIONS TO AUTHORS
The Taiwan Journal of Ophthalmology (TJO) is the peer-reviewed publication of the Ophthalmological Society of Taiwan. It is 
published quarterly by Elsevier (in March, June, September and December). The TJO publishes original contributions on all 
fields of ophthalmology and related disciplines that are of interest to the ophthalmological profession.
The Editorial Board requires authors to be in compliance with the Uniform Requirements for Manuscripts Submitted 
to Biomedical Journals (URMs), which are compiled by the International Committee of Medical Journal Editors (ICMJE); 
current URMs are available at http://www.icmje.org. 
These Instructions to Authors are revised periodically by the Editors as needed. Authors should consult a recent issue of 
the Journal or visit www.e-tjo.com for the latest version of these instructions. Any manuscript not prepared according to 
these instructions will be returned immediately to the author(s) without review.
1. Manuscript Submission
1.1. Online Submission
Manuscripts (meaning all submission items, including all text, 
tables, artwork, cover letter, conflicts of interest disclosures, and 
any other required documents/material) must be submitted 
online to the TJO through the Elsevier Editorial System (EES) 
at http://ees.elsevier.com/tjo. If assistance is required, please 
refer to the tutorials for authors and/or customer support 
that are available on the EES website; you may also contact 
the Editorial Office. Please do not post, fax or e-mail your 
manuscripts to the Editorial Office.
Editorial Office
Taiwan Journal of Ophthalmology 
11F, No. 32, Kung-Yuan Road
Taipei, Taiwan
Tel: (+886) 2-23146694
Fax: (+886) 2-23146835
1.2. Important Information
•  Articles should be in Microsoft Word document format 
and prepared in the simplest form possible. We will add 
in the correct font, font size, margins and so on according 
to the Journal’s style.
•  You may use automatic page numbering, but do NOT use 
other kinds of automatic formatting such as footnotes, 
headers and footers. References especially should NOT be 
formatted using the MS Word “endnotes” or “footnotes” 
function; instead, you may use the commercially avail-
able EndNote® or Reference Manager® software to man-
age your references. 
•  Put text, references, tables, and table/figure legends in 
one file.
•  Figures must be submitted as separate picture files, at 
the correct resolution and named according to the figure 
number and format, e.g., “Fig1.tif”, “Fig2.jpg”. Please see 
section 9.8. for more information.
1.3. Supporting Documents
The following documents must be included in your submis-
sion (refer also to the Checklist). Items (1), (2) and (3) are 
mandatory. Items (4), (5), (6) and (7) are required only if they 
are applicable to your manuscript.
(1) Cover Letter. This must include the following information:
•  title of the manuscript
•  names (spelled out in full) of all the authors*, and the 
institutions with which they are affiliated; indicate all af-
filiations with a superscripted lowercase letter after the 
author’s name and in front of the matching affiliation 
(*the name of each author should be written with the family 
name last, e.g., Wan-Lin Chang)
•  corresponding author details (name, e-mail, mailing 
address, telephone and fax numbers)
•  a statement that the material contained in the manu-
script has not been previously published and is not being 
concurrently submitted elsewhere
•  persons who do not fulfill the requirements to be listed as 
authors but who nevertheless contributed to the manu-
script (such as those who provided writing assistance, for 
example) should be disclosed
•  list of manuscripts that have been published, submit-
ted, or are in press that are similar to the submission to 
the TJO (and include in your submission copies of those 
similar manuscripts so that TJO Editors can be assured 
there is no overlap)
•  the signature of the corresponding author
Optional: if you have a list of reviewers who you wish to 
review or not to review your manuscript, you may include 
this list in the cover letter
(2) Authorship & Conflicts of Interest Statement. Each au-
thor’s contribution to the manuscript should be listed. Any 
and all potential and actual conflicts of interest should also 
be listed (see Section 2 for more information). Please use 
the TJO Authorship & Conflicts of Interest Statement form 
that is provided on the Journal’s website at www.e-tjo.
com. The corresponding author should sign on behalf of all 
the authors listed in the manuscript.
(3) Copyright Transfer Agreement. In the event that your 
manuscript is accepted for publication in the TJO, you are 
required to transfer all copyright ownership in and relat-
ing to the work to the Ophthalmologic Society of Taiwan. 
Please use the TJO Copyright Transfer Agreement form that 
is provided on the Journal’s website at www.e-tjo.com. 
Your signature and those of ALL your coauthors must be 
included. However, the Agreement will be null and void if 
your manuscript is not published in the TJO.
(4) Ethics Statement. Articles covering the use of human 
or animal samples in research, or human or animal experi-
ments must be accompanied by a letter of approval from 
the relevant review committee or authorities. See Section 
3 for more information.
(5) Consolidated Standards of Reporting Trials (CONSORT) 
flow chart for randomized controlled trials submitted for 
publication. See Section 4 for more information.
(6) Signed Statement of Informed Consent. Articles where 
human subjects can be identified in descriptions, photographs 
or pedigrees must be accompanied by a signed statement 
of informed consent to publish (in print and online) the 
descriptions, photographs and pedigrees from each subject 
who can be identified. See Section 5 for more information. 
(7) Copyright Permission. If you have reproduced or adapted 
material from other copyrighted sources, the letter(s) of 
permission from the copyright holder(s) to reproduce or 
adapt the copyrighted sources must be supplied. Otherwise, 
such material must be removed from your manuscript.
2. Disclosure of Conflicts of Interest
A conflict of interest occurs when an individual’s 
objectivity is potentially compromised by a desire for 
financial gain, prominence, professional advancement 
or a successful outcome. TJO Editors strive to ensure that 
what is published in the Journal is as balanced, objective 
and evidence-based as possible. Since it can be difficult 
to distinguish between an actual conflict of interest and a 
perceived conflict of interest, the Journal requires authors 
to disclose all and any potential conflicts of interest.
Conflicts of interest may be financial or non-financial. 
Financial conflicts include financial relationships such as 
honoraria; educational grants; participation in speakers’ 
bureaus; membership, employment, consultancies, stock 
ownership, or other equity interest; expert testimony or 
patent-licensing arrangements. Non-financial conflicts 
include personal or professional relationships, affiliations, 
academic competition, intellectual passion, knowledge or 
beliefs that might affect objectivity.
3. Ethical Approval of Studies and Informed Consent
For human or animal experimental investigations, 
appropriate institutional review board or ethics 
committee approval is required, and such approval should 
be stated in the methods section of the manuscript. For 
those investigators who do not have formal ethics review 
committees, the principles outlined in the Declaration of 
Helsinki should be followed (World Medical Association. 
Declaration of Helsinki: Ethical Principles for Medical 
Research Involving Human Subjects. Available at http://
www.wma.net/en/30publications/10policies/b3/17c.pdf).
For investigations of human subjects, state explicitly 
in the methods section of the manuscript that informed 
consent was obtained from all participating adult subjects 
and from parents or legal guardians for minors or 
incapacitated adults, together with the manner in which 
informed consent was obtained (i.e., oral or written).
For work involving animals, the guidelines for their care 
and use that were followed should be stated in the methods 
section of the manuscript. For those investigators who do 
not have formal institutional guidelines relating to animal 
experiments, the European Commission Directive 86/609/
EEC for animal experiments (available at http://ec.europa.eu/
environment/chemicals/lab_animals/legislation_en.htm) 
should be followed and the same should be stated in the 
methods section of the manuscript.
4. Reporting Clinical Trials
All randomized controlled trials submitted for publication 
should include a completed Consolidated Standards of 
Reporting Trials (CONSORT) flow chart (please go to 
www.consort-statement.org for more information). The 
TJO has adopted the ICMJE proposal that requires, as a 
condition of consideration for publication of clinical 
trials, registration in a public trials registry. Trials must 
register at or before the onset of patient enrolment. The 
clinical trial registration number should be included at 
the end of the abstract of the article.
For this purpose, a clinical trial is defined as any 
research study that prospectively assigns human 
participants or groups of humans to one or more health-
related interventions to evaluate the effects of health 
outcomes. Health-related interventions include any 
intervention used to modify a biomedical or health-related 
outcome (for example drugs, surgical procedures, devices, 
behavioral treatments, dietary interventions, and process-
of-care changes). Health outcomes include any biomedical 
or health-related measures obtained in patients or 
participants, including pharmacokinetic measures and 
adverse events.
Purely observational studies (those in which the 
assignment of the medical intervention is not at the 
discretion of the investigator) will not require registration. 
Further information can be found at http://www.icmje.org.
5. Identification of Patients in Descriptions, Photographs 
and Pedigrees
A signed statement of informed consent to publish (in 
print and online) patient descriptions, photographs and 
pedigrees should be obtained from all subjects (parents or 
legal guardians for minors) who can be identified (including 
by the subjects themselves) in such written descriptions, 
photographs or pedigrees. Such persons should be shown 
the manuscript before its submission. Omitting data 
or making data less specific to de-identify patients is 
acceptable, but changing any such data is not acceptable. 
State explicitly in the methods section of the manuscript 
that informed consent was obtained from all participating 
adult subjects or from parents or legal guardians for minors 
or incapacitated adults, together with the manner in which 
informed consent was obtained (i.e., oral or written).
6. Previous Publication or Duplicate Submission
Submitted manuscripts are considered with the understanding 
that they have not been published previously in print or 
electronic format (except in abstract or poster form) and are not 
under consideration in totality or in part by another publication 
or electronic medium.
7. Basic Criteria
Articles should be written in English (using American 
English spelling) and meet the following basic criteria: 
the material is original, the information is important, 
the writing is clear and concise, the study methods are 
appropriate, the data are valid, and the conclusions are 
reasonable and supported by the data.
8. Article Categories
The categories of articles that are published in the Journal are 
listed and described below. Please select the category that 
best describes your paper. If your paper does not fall into any 
of these categories, please contact the Editorial Office.
8.1. Review and Systematic Review Articles 
These should aim to provide the reader with a balanced 
overview of an important and topical subject in the 
field, and should be systematic and critical assessments 
of literature and data sources. They should cover aspects 
of a topic in which scientific consensus exists as well 
as aspects that remain controversial and are the subject of 
ongoing scientific research. All articles and data sources 
reviewed should include information about the specific 
type of study or analysis, population, intervention, 
exposure, and tests or outcomes. All articles or data 
sources should be selected systematically for inclusion 
in the review and critically evaluated. The text (including 
references) should not exceed 4500 words.
8.2. Special Reports
These are miscellaneous articles of special interest to the 
ophthalmological community; limited to 4500 words.
8.3. Editorials
Editorials are invited articles or comments concerning 
a specific paper in the Journal. They should be limited to 
1500 words with no more than 15 references. Although 
editorials are normally invited, unsolicited editorials may 
be submitted.
8.4. Original Articles
These may be randomized trials, intervention studies, 
studies of screening and diagnostic tests, laboratory and 
animal studies, cohort studies, cost-effectiveness analy-
ses, case-control studies, and surveys with high response 
rates, which represent new and significant contributions 
to the field.
Section headings should be: Abstract, Introduction, 
Methods, Results, Discussion, Acknowledgments (if any), 
References.
The Introduction should provide a brief background 
to the subject of the paper, explain the importance of the 
study, and state a precise study question or purpose.
The Methods section should describe the study design 
and methods (including the study setting and dates, pa-
tients/participants with inclusion and exclusion criteria, 
patient samples or animal specimens used, the essential 
features of any interventions, the main outcome measures, 
the laboratory methods followed, or data sources and how 
these were selected for the study), and state the statistical 
procedures employed in the research.
The Results section should comprise the study results pre-
sented in a logical sequence, supplemented by tables and/or 
figures. Take care that the text does not repeat data that are 
presented in the tables and/or figures. Only emphasize and 
summarize the essential features of the main results.
The Discussion section should be used to emphasize the 
new and important aspects of the study, placing the results in 
context with published literature, the implications of the find-
ings, and the conclusions that follow from the study results.
The text (including references) should not exceed 3500 
words.
8.5. Brief Communications
These should clearly and concisely describe clinical or 
technical notes, preliminary experimental results or 
instrumentation and analytic techniques. Section head-
ings should be: Abstract, Introduction, Methods, Results, 
Discussion, Acknowledgments (if any), References. The 
text should not exceed 2000 words with no more than 20 
references. The Editors reserve the right to decide what 
constitutes a Brief Communication.
8.6. Case Reports
These are short discussions of a case or case series with 
unique features not previously described that make an 
important teaching point or scientific observation. They 
may describe novel techniques, novel use of equipment, 
or new information on diseases of importance. Section 
headings should be: Abstract, Introduction, Case Presen-
tation, Discussion, Acknowledgments (if any), References.
The Introduction should describe the purpose of the re-
port, the significance of the disease and its specificity, and 
briefly review the relevant literature.
The Case Presentation should include the general data 
of the case, medical history, family history, chief com-
plaint, present illness, clinical manifestation, methods of 
diagnosis and treatment, and outcome.
The Discussion should compare, analyze and discuss 
the similarities and differences between the reported case 
and similar previously reported cases. The importance or 
specificity of the case should be restated when discuss-
ing the differential diagnoses. Suggest the prognosis of the 
disease and possibility of prevention.
The text (including references) should not exceed 2000 
words.
8.7. Letters to the Editor
These include brief constructive comments concerning pre-
viously published articles, interesting cases that do not meet 
the requirement of being truly exceptional, and other com-
munications of general interest. Letters should have a title 
and include appropriate references, and include the corre-
sponding author’s mailing and e-mail addresses. Letters are 
edited, sometimes extensively, to sharpen their focus. They 
may be sent for peer review at the discretion of the Editors. 
The text should not exceed 600 words with no more than 
5 references; 1 table and/or 1 figure may be included.
9. Manuscript Preparation
Text should be typed double-spaced on one side of white 
A4 (210 × 297 mm) paper, with outer margins of 2.5 cm. 
A manuscript should include a title page, abstract, key-
words, main text, acknowledgments (if any), references, 
and figures and tables as appropriate. Each section of the 
manuscript should begin on a new page. Pages should be 
numbered consecutively, beginning with the title page.
9.1. Title Page
The title page should contain the following information (in 
order, from the top to the bottom of the page):
• article category
• article title
•  declaration of any potential financial and non-financial 
conflicts of interest
 IMPORTANT: please do NOT include any author names and 
affiliations or corresponding author information on the 
title page (this information should be listed in your cover 
letter instead) because the TJO follows a double-blind peer 
review process
9.2. Abstract and Keywords
Abstracts should be no more than 300 words in length. 
 Abstracts for Original Articles should be structured, 
with the section headings: Background/Purpose, Meth-
ods,  Results, Conclusion. Abstracts for Case Reports are 
 unstructured, but should include the significance and 
purpose of the case presentation, the diagnostic methods 
of the case, the key data, and brief comments and sug-
gestions with regard to the case. Abstracts for Review Ar-
ticles and Brief Communications should also be unstruc-
tured. An abstract is often presented separately from the 
article, so it must be able to stand alone. For this reason, 
References should be avoided, but if essential, then cite 
the author(s) and year(s). Also, non-standard or uncom-
mon abbreviations should be avoided, but if essential they 
must be defined at their first mention in the abstract it-
self. No abstract is required for Editorials and Letters to 
the Editor. 
For all article categories, 3–5 relevant keywords taken 
from the MeSH list of Index Medicus (www.nlm.nih.gov/
mesh/meshhome.html) should be provided in alphabeti-
cal order. Avoid general and plural terms and multiple 
concepts (avoid, for example, “and”, “of”). Be sparing with 
abbreviations: only abbreviations firmly established in the 
field may be eligible.
9.3. Main Text
The text for Original Articles should be organized into 
the  following sections: Introduction, Methods, Results, 
 Discussion. Sections for Case Reports are: Introduction, 
Case Presentation, Discussion. Each section should begin 
on a new page.
Each heading and subheading should be numbered, e.g., 
“1. Introduction”, “2. Methods”, “2.1. Patients”, “2.2. Statistical 
analyses”, etc. Use these section numbers for internal cross-
referencing if necessary: do not just refer to “the text”. Each 
heading should appear on its own line.
9.3.1. Abbreviations
Where a term/definition will be continually referred to, it 
must be written in full when it first appears in the text, 
followed by the subsequent abbreviation in parentheses 
(even if it was previously defined in the abstract). Thereaf-
ter, the abbreviation may be used. An abbreviation should 
not be first defined in any section heading; if an abbre-
viation has previously been defined in the text, then the 
abbreviation may be used in a subsequent section head-
ing. Restrict the number of abbreviations to those that are 
absolutely necessary and ensure consistency of abbrevia-
tions throughout the article. Ensure that an abbreviation 
so defined does actually appear later in the text (excluding 
in figures/tables), otherwise, it should be deleted.
9.3.2. Numbers
Numbers that begin a sentence or those that are less than 
10 should be spelled out using letters. Centuries and dec-
ades should be spelled out, e.g., the Eighties or nineteenth 
century. Laboratory parameters, time, temperature, length, 
area, mass, and volume should be expressed using digits.
9.3.3. Units
Système International (SI) units must be used, with 
the exception of blood pressure values which are to be 
reported in mmHg. Use the metric system for the expres-
sion of length, area, mass, and volume. Temperatures are 
to be given in degrees Celsius.
9.3.4. Names of drugs, devices and other products
Use the Recommended International Non-proprietary 
Name (rINN) for medicinal substances, unless the specific 
trade name of a drug is directly relevant to the discussion. 
Generic drug names should appear in lowercase letters 
in the text. If a specific proprietary drug needs to be 
identified, the brand name may appear only once in the 
manuscript in parentheses following the generic name the 
first time the drug is mentioned in the text.
For devices and other products, the specific brand or 
trade name, the manufacturer and their location (city, 
state, country) should be provided the first time the 
device or product is mentioned in the text, for example, 
“…IBM SPSS Statistics 21.0 was used (IBM Corp., Armonk, 
NY, USA)”. Thereafter, the generic term (if appropriate) 
should be used.
9.3.5. Gene nomenclature
Current standard international nomenclature for genes 
should be adhered to. For human genes, use genetic 
notation and symbols approved by the HUGO Gene 
Nomenclature Committee (www.genenames.org). You 
may also refer to the resources available on PubMed 
at www.ncbi.nlm.nih.gov/guide/genes-expression. The 
Human Genome Variation Society has a useful site that 
provides guidance in naming mutations at www.hgvs.org/
mutnomen/index.html. In your manuscript, genes should 
be typed in italic font and include the accession number.
9.3.6. Statistical requirements
Statistical analysis is essential for all research papers 
 except Case Reports. Use correct nomenclature for 
statistical methods (e.g., two sample t test, not unpaired t 
test). Descriptive statistics should follow the scales used 
in data description. Inferential statistics are important 
for interpreting results and should be described in detail. 
All p values should be presented to the third decimal place 
for accuracy. The smallest p value that should be expressed 
is p < 0.001 since additional zeros do not convey useful 
information; the largest p value that should be expressed is 
p > 0.99.
9.3.7. Personal communications and unpublished data
These sources cannot be included in the references list 
but may be described in the text. The author(s) must give 
the full name and highest academic degree of the person, 
the date of the communication, and indicate whether it 
was in oral or written (letter, fax, e-mail) form. A signed 
 statement of permission should be included from each 
person identified as a source of information in a  personal 
communication or as a source for unpublished data.
9.4. Funding/Support Statement
All financial and material support for the research, work, 
writing and editorial assistance from internal or external 
agencies, including commercial companies, should be 
clearly and completely identified in a Funding/Support 
Statement.
9.5. Acknowledgments
General acknowledgments for consultations and statistical 
analyses should be listed concisely, including the names 
of the individuals who were directly involved. Consent 
should be obtained from those individuals before their 
names are listed in this section. Those acknowledged 
should not include secretarial, clerical or technical staff 
whose participation was limited to the performance of 
their normal duties.
9.6. References
Authors are responsible for the accuracy and completeness 
of their references and for correct in-text citation.
9.6.1. In the main text, tables and figure legends
•  References should be indicated by superscripted Arabic 
numerals, numbered consecutively in order of appear-
ance. The numerals should be placed outside periods and 
commas, and inside colons and semicolons. [The actual 
authors can be referred to, but the reference number(s) 
must always be given.]
•  References cited in tables or figure legends should be in-
cluded in sequence at the point where the table or figure 
is first mentioned in the main text.
•  Do not cite abstracts unless they are the only available 
reference to an important concept.
•  Do not cite uncompleted work or work that has not yet 
been accepted for publication (i.e., “unpublished obser-
vation”, “personal communication”) as references. Also 
see Section 9.3.7.
9.6.2. In the references list
•  References should be compiled at the end of the manu-
script according to the order of citation in the text.
•  References should be limited to those cited in the text 
only.
•  Journal references should include, in order, authors’ sur-
names and initials, article title, abbreviated journal name, 
year, volume and inclusive page numbers.
•  The surnames and initials of all the authors up to 6 should 
be included, but when authors number 7 or more, list the 
first 3 authors only followed by “et al”.
•  Abbreviations for journal names should conform to those 
used in MEDLINE.
•  If citing a website, provide the author information, 
article title, website address and the date you accessed 
the information.
•  Reference to an article that is in press must state the 
journal name and, if possible, the year and volume.
Examples of the most common reference types are 
provided below. (Please pay particular attention to the 
formatting, word capitalization, spacing and style.)
Standard journal articles
Bisdas T, Pichlmaier M, Wilhelmi M, Bisdas S, Haverich A, 
Teebken O. Effects of the ABO-mismatch between donor 
and recipient of cryopreserved arterial homografts. Int 
Angiol. 2011;30:247–255.
Quintini C, D’Amico G, Brown C, et al. Splenic artery em-
bolization for the treatment of refractory ascites after liver 
transplantation. Liver Transpl. 2011;17:668–673.
Journal supplement
Kaplan NM. The endothelium as prognostic factor and 
therapeutic target: what criteria should we apply? 
J Cardiovasc Pharmacol. 1998;32(Suppl. 3):S78–80.
Journal article not in English but with English abstract
Kawai H, Ishikawa T, Moroi J, et al. Elderly patient with 
cerebellar malignant astrocytoma. No Shinkei Geka. 
2008;36:799–805. [In Japanese, English abstract]
Book with edition
Bradley EL. Medical and Surgical Management. 2nd ed. Phil-
adelphia, PA: WB Saunders; 1982.
Book with editors
Letheridge S, Cannon CR, eds. Bilingual Education: Teaching 
English as a Second Language. New York, NY: Praeger; 1980.
Book chapter in book with editor and edition
Levitt MD. Pancreatitis. In: Sleisenger MH, ed. Cecil Text-
book of Medicine. 18th ed. Philadelphia, PA: WB Saunders; 
1988:774–780.
Book series with editors
Wilson JG, Fraser FC, eds. Handbook of Teratology, Vols. 1–4. 
New York, NY: Plenum Press; 1977–1978.
Bulletin
Substance Abuse and Mental Health Services Administra-
tion. Emergency Department Trends from the Drug Abuse 
Warning Network, Final Estimates 1995–2002. Rockville, 
MD: Substance Abuse and Mental Health Services Admin-
istration, Office of Applied Statistics; 2003.
Electronic publications
Duchin JS. Can preparedness for biological terrorism save 
us from pertussis? Arch Pediatr Adolesc Med. 2004;158(2). 
Available at http://archpedi.ama-assn.org/cgi/content/
full/158/2/106. Accessed June 12, 2004.
Smeeth L, Iliffe S. Community screening for visual im-
pairment in the elderly. Cochrane Database Syst Rev. 
2002(2):CD001054. Doi:10.1002/14651858.CD1001054.
Thesis
Griffiths P. Nursing Patients in Transition: An Ethnography of 
the Role of the Nurse on an Acute Medical Admissions Unit. PhD 
thesis. Wales, UK: University of Wales; 2007.
Website
NICE—National Institute for Health and Care Excellence. 
Acute Upper Gastrointestinal Bleeding: Management (CG141). 
London, UK: NICE; 2012. Available at http://publications.
nice.org.uk/acute-upper-gastrointestinal-bleeding-man-
agement-cg141. Accessed April 15, 2013.
9.7. Tables
Tables should supplement, not duplicate, the text. They 
should have a concise table heading, be self-explanatory, 
and numbered consecutively in the order of their cita-
tion in the text. Items requiring explanatory footnotes 
should be denoted using superscripted lowercase letters 
(a, b, c, etc.), with the footnotes arranged under the table in 
alphabetical order. Asterisks (*, **) are used only to indicate 
the probability level of tests of significance. Abbreviations 
used in the table must be defined and placed after the foot-
notes in alphabetical order. If you include a block of data 
or table from another source, whether published or unpub-
lished, you must acknowledge the original source.
9.8. Figures
9.8.1. General guidelines
The number of figures should be restricted to the minimum 
necessary to support the textual material. Figures should 
have an informative figure legend and be numbered in the or-
der of their citation in the text. All symbols and abbreviations 
should be defined in the figure legend in alphabetical order. 
Items requiring explanatory footnotes should follow the same 
style as that for tables as described in Section 9.7.
Unless you have written permission from the patient (or, 
where applicable, the next of kin), the personal details (such 
as their name and date of birth) of the patient must be re-
moved. If their face is shown, use a black bar to cover their 
eyes so that they cannot be identified (for further informa-
tion, see www.elsevier.com/patientphotographs).
All lettering should be done professionally and should be 
in proportion to the drawing, graph or photograph. Photomi-
crographs must include an internal scale marker, and the leg-
end should state the type of specimen, original magnification 
and stain.
Figures must be submitted as separate picture files, at the 
correct resolution (see Section 9.8.2.) and named according to 
the figure number and format, e.g., “Fig1.tif”, “Fig2.jpg”.
9.8.2. Formats
Regardless of the application used, when your electronic 
artwork is finalized, please “save as” or convert the images 
to one of the following formats (note the resolution 
requirements for line drawings, halftones, and line/halftone 
combinations given below):
•  EPS: vector drawings. Embed the font or save the text as 
“graphics”.
•  TIFF: color or grayscale photographs (halftones)—always 
use a minimum of 300 dpi.
•  TIFF: bitmapped line drawings—use a minimum of 1000 dpi.
•  TIFF: combination of bitmapped line/half-tone (color or 
grayscale)— use a minimum of 600 dpi.
•  DOC, XLS or PPT: if your electronic artwork is created in any 
of these Microsoft Office applications, please supply “as is”.
Please do not:
•  Supply files that do not meet the resolution requirements 
detailed above;
•  Supply files that are optimized for screen use (such as GIF, 
BMP, PICT, WPG) as the resolution is too low;
•  Submit graphics that are disproportionately large for the 
content.
A detailed guide on electronic artwork is available at www.
elsevier.com/artworkinstructions. Please note that the cost of 
color illustrations will be charged to the author (see Section 12 
for more information).
10. The Editorial and Peer Review Process
As a general rule, the receipt of a manuscript will be ac-
knowledged within 2 weeks of submission; authors will be 
provided with a manuscript reference number for future 
correspondence. If an acknowledgment is not received in 
a reasonable period of time, the author should contact the 
Editorial Office.
Submissions are reviewed by the Editorial Office to en-
sure that it contains all parts. Submissions will be rejected if 
the author has not supplied all the material and documents 
as outlined in these author instructions.
Manuscripts are then forwarded to the Editor-in-Chief, 
who makes an initial assessment of it. If the manuscript 
does not appear to be of sufficient merit or is not appropri-
ate for the Journal, the manuscript will be rejected without 
review.
Manuscripts that appear meritorious and appropriate 
for the Journal are sent to 2 or more expert consultants for 
double-blind peer review. Authors will usually be notified 
within 8 weeks of the initial acknowledgment of whether 
the manuscript is accepted for publication, rejected, or sub-
ject to revision before acceptance. However, do note that 
delays are sometimes unavoidable. If revisions are required, 
authors are asked to return a revised manuscript to the Ed-
itorial Office via the EES within 30 days. Please notify the 
Editorial Office in advance if additional time is needed or if 
you choose not to submit a revised manuscript.
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